Toxicity and Safety Evaluation of Doxorubicin-Loaded Cockleshell-Derived Calcium Carbonate Nanoparticle in Dogs

Figure 4

Effect of treatment groups from onset to 3 weeks after the 5th cycle on the haematological profile and serum biochemistry. (a) Red blood cells (RBCs) (10⁶/mm³), (b) platelet cells (PLT) (10³/mm³), (c) white blood cells (WBC) (10³/mm³), (d) alkaline phosphatase (ALP) (µ/L), (e) aspartate aminotransferase (AST) (µ/L), (f) alanine aminotransferase (ALT) (µ/L), (g) lactate dehydrogenase (LDH) (µ/L), (h) creatinine kinase (CK) (µ/L), (i) creatinine (Crea) (µmol/L), and (j) urea (mmol/L). Values are expressed as mean ± standard deviation. Different alphabets indicate statistical significance () between groups at different cumulative doses with a, b, c, and d representing significant difference with control, DOX 30 mg/m², CS-CaCO₃NP-DOX 50 mg/m², CS-CaCO₃NP-DOX 30 mg/m², and CS-CaCO₃NP-DOX 20 mg/m², respectively.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)